Virobay
Discovering the posibilities
2006 – Founded as a protease inhibitor drug discovery and development company
2007 – Filed IND and initiated Phase I trial with lead protease inhibitor as an oral treatment for Hepatitis C
2007 – In-licensed cathepsin protease inhibitor assets; including VBY-129, a selective cathepsin S inhibitor which completed phase 1 clinical development
2008 – Virobay assets solve the chemical challenge of cathepsin inhibitor design; multiple orally bioavailable development candidates are poised for Phase I
2010 – Virobay closes Series B financing
About Virobay
- Founded in 2006 our scientists have applied their extensive knowledge and experience designing selective protease inhibitors to the cathepsin family of proteases. Members of the cathepsin family are implicated as key mediators in the pathology of diseases, including certain autoimmune disorders, neuropathic pain, liver diseases, atherosclerosis, osteoporosis, COPD and cancer. Virobay compounds are highly potent, orally active and drug-like, addressing common problems in the design of cathepsin inhibitors. Virobay’s cathepsin inhibitors include compounds that are highly specific for individual cathepsins (e.g., cathepsin S) as well as compounds that are broadly active against multiple cathepsins.
- Our management team, based in Menlo Park, California has decades of experience in drug development, including leadership roles at Roche, Wellcome, Sugen and Celera Genomics
- As a virtual company, Virobay in-house expertise is complemented by the extensive resources available at contract facilities world-wide, creating operational flexibility for cost effective and efficient drug discovery and development.
